The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Plasmid DNA is circular double stranded DNA molecules capable of autonomous replication distinct from chromosomal DNA. They are important tools in genetic engineering, gene therapy, transgenic technology and other basic research as they can be modified, amplified and transferred between organisms. Plasmid DNA manufacturing plays an important role in production of DNA/RNA based vaccines, gene therapies and other advanced therapies.

Segment Analysis
The global plasmid DNA manufacturing market is segmented into vector type, application, end user and region. Based on vector type, the market is divided into bacterial plasmid vectors and non-bacterial plasmid vectors. The bacterial plasmid vectors segment dominates the market as they are inexpensive and easy to produce when compared to non-bacterial plasmid vectors. By application, the market is categorized into gene and cell therapy, DNA vaccines, cancer therapy, and others. The gene and cell therapy segment holds the largest market share owing to the increasing R&D in gene therapies for treating genetic disorders. On the basis of end user, the market is bifurcated into biopharmaceutical companies, research organizations, and contract manufacturing organizations. Biopharmaceutical companies dominate the market due to high adoption of plasmid DNA for manufacturing therapies and vaccines. 

Read More

https://healthcarelatesteditionnews.blogspot.com/2023/11/the-plasmid-dna-manufacturing-is.html